AstraZeneca: Externally Sponsored Scientific Research (ESR) – Oncology Focus
Independent investigators are invited to submit clinical and translational proposals on AstraZeneca oncology compounds, ranging from bispecific T-cell engagers and ATM inhibitors to antibody-drug conjugates and immune checkpoint modulators. Priority is given to studies that complement the core development programme and address unmet clinical needs.
Eligibility Criteria:
-
Non-company researchers at academic medical centres or cancer institutes.
-
Proposals must align with the specified areas of interest for each compound and not compete directly with ongoing registrational trials.
-
Full compliance with GCP and local regulations is mandatory.
Funding Details:
-
Support Type: Drug-only support, combination-strategy resources, biomarker assay kits, and translational-lab access.
-
Key Compounds & Interests:
-
AZD0486 (CD19×CD3 TCE): Combination and sequencing strategies in indolent NHL subtypes (WM/LPL, FL).
-
AZD1390 (ATM inhibitor): Monotherapy or combination with radiotherapy for solid tumours.
-
Calquence (acalabrutinib): RWE and mechanistic studies in CLL/SLL, MCL, iNHL, and DLBCL.
-
Dato-DxD (datopotamab deruxtecan): AE-management and efficacy in NSCLC and breast-cancer populations, including resistance mechanisms and underrepresented cohorts.
-
Enhertu (trastuzumab deruxtecan): Expansion into early-stage, HER2-low, and non-breast indications with real-world and mechanistic endpoints.
-
Imfinzi (durvalumab): Biomarker-driven studies in NSCLC, SCLC, urothelial cancer, BTC, and HCC, plus novel screening approaches.
-
Tagrisso (osimertinib): Resistance-overcoming strategies, biomarker-driven staging, and early-disease diagnostics.
-
Truqap (capivasertib): AKT-pathway targeting and adherence studies in HR+ metastatic breast cancer.
-
Deadline:
Continuous submission; decisions within 45 days of receipt.
Where to Go for Further Information:
Register at the AstraZeneca Open Innovation ESR portal. Reach out to the Oncology medical liaison for compound-specific guidance.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023